Lifestyle Intervention in Fatty Liver (NAFLD) — FOIEGRAS  

Non-Alcoholic Fatty Liver Disease Clinical Trial

Official title: Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Liver Disease

Status Recruiting

Clinical Trial Summary

Non-Alcoholic Fatty Liver Disease (NAFLD), including its more pathologic consequence, non-alcoholic steatohepatitis (NASH), is believed to be the most common chronic liver disease worldwide, affecting between 6 to 37% of the population. NAFLD is a so called 'silent killer', as clinical symptoms only surface at late stages of the disease, when it is no longer treatable: untreated, NAFLD/NASH can lead to cirrhosis and hepatocellular carcinoma, culminating in liver failure. Several factors may contribute to the pathogenesis of NAFLD, including genetic assessment and mitochondrial dysfunction. Patients with NAFLD/NASH display disturbances of intestinal permeability, and gut microbiota. In the most of cases, NAFLD/NASH is strongly linked to other metabolic conditions, including visceral adiposity. Currently the best method of diagnosing and staging the disease is liver biopsy, a costly, invasive and somewhat risky procedure, not to mention unfit for routine assessment. Weight loss is the first step approach with reasonable evidence suggesting it is beneficial and safe in NAFLD/NASH patients. However, the efficacy of weight reduction for the treatment of NAFLD/NASH has not been carefully evaluated. Several studies on the effects of weight reduction on NAFLD/NASH have been uncontrolled, used poorly defined patient populations and non-standardized weight loss interventions, and lacked a well-accepted primary outcome for NASH.

The objective of the project is to conduct a randomized controlled trial of 1 year-long weight reduction in the management of NAFLD/NASH patients using a lifestyle-dietary intervention program. Overweight or obese individuals with biopsy or ultrasonography (US) -proven NAFLD/NASH will be randomized to receive either standard medical care and educational sessions related to NAFLD/NASH, healthy eating, weight loss, and exercise (control group); or to an intensive weight management with a goal of at least 7-10 % weight reduction (lifestyle intervention group). The weight loss intervention will be modelled on Mediterranean-intervention-diet. The investigators hypothesize that a 7-10% weight reduction through intensive lifestyle intervention will lead to improvement of clinical, US, anthropometric, and biochemical features on patients diagnosed with NAFLD/NASH.

Clinical Trial Description

Background

Non-Alcoholic Fatty Liver Disease (NAFLD), including its more pathologic consequence, non-alcoholic steatohepatitis (NASH), is believed to be the most common chronic liver disease worldwide, affecting between 6 to 37% of the population. NAFLD is a so called 'silent killer', as clinical symptoms only surface at late stages of the disease, when it is no longer treatable. Untreated, NAFLD/NASH can lead to cirrhosis and hepatocellular carcinoma, culminating in liver failure. Several factors may contribute to the pathogenesis of NAFLD, including genetic assessment and mitochondrial dysfunction. Genetic factors might affect the pathophysiological aspects of NAFLD and its natural history. The European population appears to host genetic variants which can play a role in this respect. Recently, the common variant p.I148M of the enzyme adiponutrin (PNPLA3) has emerged as a major genetic determinant of hepatic steatosis and non-alcoholic steatohepatitis as well as its pathobiological sequelae fibrosis, cirrhosis, and hepatocellular cancer. PNPLA3 encodes a lipid droplet-associated, carbohydrate-regulated lipogenic and/or lipolytic enzyme. Homozygous carriers of the PNPLA3 variant (i.e. the presence of the PNPLA3 allele [M]) are prone to develop cirrhosis in the absence of other risk factors such as alcohol or viral hepatitis. Moreover, PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery, in comparison to carriers of PNPLA3 wild-type alleles.

Other variants might also play a role and include transmembrane 6 superfamily member 2 (TM6SF2) p.E167K, and membrane-bound O-acyltransferase domain containing 7 (MBOAT7) rs641738. Neither PNPLA3 nor TM6SF2 risk alleles impair the response to dietetic intervention in NAFLD. MBOAT7 polymorphism is associated with increased triglyceride, total cholesterol, low density lipoprotein, and serum glucose levels, all factors associated with metabolic syndrome and liver steatosis.

Patients with NAFLD/NASH display disturbances of intestinal permeability, and gut microbiota. In most cases, NAFLD/NASH is strongly linked to other metabolic conditions, including visceral adiposity.

Liver biopsy is the gold standard for the diagnosis and staging of NAFLD but is invasive in nature and not easily usable as screening tool. Other imaging techniques include ultrasonography which is non-invasive, can detect hepatic steatosis (>20%-30%) and can be easily used in follow-up studies. Computerized tomography, magnetic resonance imaging, and spectroscopy are alternative imaging techniques used for the detection of hepatic steatosis. However, they have failed to show better accuracy, are expensive and can bring adverse effects (e.g., radiation). Therefore they are not feasible as screening tools. Liver enzymes represent surrogate markers of liver disease but have limited accuracy. By ultrasound, NAFLD prevalence ranges from 11%-30%. In the United States, ultrasonographic NAFLD appears to range between 5%-33%. Liver fibrosis may be non-invasively assessed by acoustic radiation force impulse imaging (ARFI), an ultrasound-based approach for estimating liver stiffness, a surrogate marker of liver fibrosis. ARFI imaging is based on short-duration, high-intensity acoustic pulses to produce mechanical excitation in tissue. Localized tissue displacement and shear wave propagation follow the tissue excitation. The velocity of the waves correlates with the degree of fibrosis, implying that the shear wave velocity increases as the amount of fibrosis increases. Optimal cut-off values are provided by various studies. In the study by Crespo et al. (2012), the sensitivity of ARFI imaging in 88 patients for ≥F2 fibrosis was 85% using a cut-off of 1.44 m/s and for F4 fibrosis was 92 percent using a cut-off of 1.9 m/s. The corresponding specificities were 76 and 87 percent, respectively. In another study, ARFI was compared with ultrasound-based transient elastography in 321 patients undergoing liver biopsy for chronic liver disease. No difference was found between ARFI and ultrasound-based transient elastography for the diagnosis of cirrhosis or severe fibrosis and ARFI was better in lean patients. Among non-obese patients the area under the receiver operating characteristic (ROC) curves for cirrhosis and severe fibrosis were 0.92 and 0.91, respectively. For obese patients they were 0.63 and 0.63, respectively.

Several serologic markers, either direct or indirect, have been elaborated but not invariably validated. Major limitations include the fact they are considered as surrogates, not biomarkers, none of the markers are liver-specific (concurrent sites of inflammation may contribute to serum levels) and because they typically reflect the rate of matrix turnover, not deposition, results tend to be more elevated when the inflammatory activity is high. On the other end, even in the presence of minimal inflammation, extensive matrix deposition can occur. Lastly, serum levels are influenced by clearance rates (i.e. not only sinusoidal endothelial cell dysfunction but also impaired biliary excretion) (Table 3). Overall, studies of the various panels suggest that serologic tests have good ability to differentiate patients with significant fibrosis (F2 to F4) from those without significant fibrosis (F0 to F1), although no standard test has emerged so far yielding definitive distinction between different types of F scores.

Breath Tests (BT) represent novel indirect "dynamic" tools which provide additional insights in functional diagnosis and follow-up of patients with liver diseases.

Principles of BTs in hepatology are based on both biochemical and pharmacological considerations. Mechanisms of liver damage often include dysfunction of subcellular organelles such as microsomal hypertrophy, mitochondrial abnormalities, activation of peroxisomal metabolism (i.e. long chain fatty acids). Thus, assessing specific functions of such organelles by BTs may provide useful information to clinicians. Also, BTs allow the study of specific time-dependent metabolic processes by assessing the hepatic clearance of metabolically active substances. In this context, for a given exogenous substrate:

HEPATIC CLEARANCE = HEPATIC PERFUSION x HEPATIC EXTRACTION (where HEPATIC EXTRACTION is the ratio of the difference between inflow and outflow concentration ÷ by inflow concentration of the probe).

Hepatic clearance is defined as flow-limited (range 0.7-1.0) or enzyme-limited (<0.3).

The intrinsic complexity of liver metabolic pathways does not allow a single functional test to explore the whole liver function. Different substrates are therefore used to assess cytosolic, microsomal or mitochondrial function. Such substrates are marked with the natural stable isotope of carbon 13C (currently the most widely used isotope). After intestinal absorption, the given substrate undergoes liver metabolism at different levels which ultimately results in the production and appearance of 13CO2 in expired air, as a marker of specific liver metabolic functions.

BTs for the study of liver microsomal function include the use of methacetin, a derivative of phenacetin which is metabolized rapidly by the hepatic microsomal enzyme systems CYP1A2 into acetaminophen and 13CO2 by a single O-dealkylation step. Since methacetin has a high extraction (E>0.8) and undergoes extensive first-pass clearance, its metabolism can be altered by hepatic blood flow alterations and by hepatic "first-pass" effect. The methacetin metabolizing capacity is lower in elderly than adults. Methacetin BT was shown to accurately assess the degree of liver damage in patients with histologically proven chronic liver diseases and to distinguish chronic aggressive hepatitis from liver cirrhosis and between early cirrhosis (Child A) from non-cirrhotic patients. Methacetin BT was a useful predictive markers of clinical outcomes in chronic HCV patients. Moreover, methacetin BT can better estimate the degree of fibrosis in patients with chronic HCV infection than biochemical parameters (i.e. aspartate aminotransferase to platelet ratio, aspartate aminotransferase to alanine aminotransferase ratio) or Fibroindex. Ketoisocaproate (KICA) is an intermediate in the metabolism of leucine. The decarboxylation of KICA and the generation of CO2 reflects the mitochondrial branched-chain amino acid decarboxylation function. This step is observed when the transamination to leucine (the major competing pathway for KICA elimination) is suppressed by the concomitant administration of fixed doses of leucine. This metabolic pathway of KICA has been tested in experimental models, in isolated mitochondria, in healthy subjects treated with acetylsalicylic acid or with low ethanol intake, and in patients with liver diseases. We found that the mitochondrial decarboxylation capacity of KICA was lower in patients with advanced non-alcoholic steatohepatitis (NASH) compared with healthy subjects and patients with simple liver steatosis. Notably, the 13CO2 cumulative recovery values following 13C-KICA was inversely related to the extent of fibrosis, to serum hyaluronate, and to body size in NASH patients. We extended the studies with 13C-KICA BT and found that KICA decarboxylation was significantly lower in cirrhotic patients with hepatocellular carcinoma (HCC) compared with cirrhotic patients without HCC and identical Child-Pugh score. Moreover, KICA decarboxylation was deranged following radiofrequency ablation but not after transarterial chemoembolization. Finally, the recurrence of HCC was associated with an early decrease of KICA decarboxylation. In a different context, we recently found that 13C-KICA BT was abnormal (and therefore suggesting mitochondrial malfunction) in a female patient suffering from massive liver echinococcosis. Of note, mitochondrial liver function improved following pericystectomy and limited hepatectomy. KICA BT is useful for the assessment of drug effects on liver mitochondrial function. Liver injury might occur following the use of such drugs which accumulate into mitochondria and interfere with respiratory complexes or electron transfer. KICA BT may be helpful to ascertain the integrity of these organelles before the administration of potentially toxic drugs and to detect drug-induced mitochondrial damage before the appearance of symptoms in order to timely manage patients and prevent adverse effects. Examples are tacrolimus, aspirin, and ergot alkaloids. Potential applications are also with amiodarone, valproate, and retroviral drugs.

Aim of the study

The objective of the mtFOIE GRAS Uniba H2020 Project is to conduct a randomized controlled trial of 3 year-long weight reduction in the management of NAFLD/NASH patients using a lifestyle-dietary intervention program. Overweight or obese individuals with biopsy or ultrasonography (US) -proven NAFLD/NASH will be randomized to receive either standard medical care and educational sessions related to NAFLD/NASH, healthy eating, weight loss, and exercise (control group); or to an intensive weight management with a goal of at least 7-10 % weight reduction (lifestyle intervention group). The weight loss intervention will be modelled on Mediterranean-intervention-diet. We hypothesize that a 7-10% weight reduction through intensive lifestyle intervention will lead to improvement of clinical, US, anthropometric, and biochemical features of NAFLD/NASH as well as of intestinal permeability and faecal microbiota. ;

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-Alcoholic Fatty Liver Disease

• NCT number: NCT03354247
• Study type: Interventional
• Source: University of Bari
• Contact: Piero Portincasa, MD, PhD
• Phone: +39 0805478227
• Email: piero.portincasa@uniba.it
• Status: Recruiting
• Phase: N/A
• Start date: July 1, 2017
• Completion date: December 31, 2020